Shockwave Medical and CRISPR Therapeutics Beat Expectations in Q1 Earnings, Ocular Therapeutix Falls Short
- May 08th, 2023
- 573 views
Shockwave Medical, Inc. (Nasdaq: SWAV) reported better-than-expected Q1 earnings, with an EPS of $1.03 versus the consensus estimate of $0.81. In after-hours trading, SWAV is up $10.04 (+3.65%) and is currently trading at $285.00.
On the other hand, CRISPR Therapeutics AG (Nasdaq: CRSP) reported a Q1 loss of $0.67 per share, which was better than the consensus estimate of a loss of $1.70 per share. As a result, in after-hours trading, CRSP is up $0.54 (+0.96%) and is currently trading at $56.50.
Finally, Ocular Therapeutix, Inc. (Nasdaq: OCUL) reported a Q1 loss of $0.39 per share, worse than the consensus estimate of a loss of $0.26 per share. As a result, in after-hours trading, OCUL is down $0.30 (-4.69%) and is currently trading at $6.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login